Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system.

Consistent observations have been described in clinical registries and pharmacovigilance analyses of combined antithrombotic therapy, indicating an overall trend toward increased bleeding and cytopenic risks relative to single agent use [ 57 ].

also in 4,871 other papers